Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.06 USD
-0.02 (-1.85%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GANX 1.06 -0.02(-1.85%)
Will GANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Other News for GANX
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
7 Sorry Biotech Stocks Set to Make Investors Sad
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson?s Disease
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday